Lupin Limited

Equities

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. 06:12:53 2024-03-28 am EDT 5-day change 1st Jan Change
1,618 INR +1.23% Intraday chart for Lupin Limited +0.35% +22.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lupin to Transfer Trade Generics Business to Subsidiary Lupin Life Sciences MT
Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms MT
Lupin Names Chief Technical Operations Officer MT
Lupin Limited Appoints Christoph Funke as Chief Technical Operations Officer CI
Boehringer to cut out-of-pocket costs for inhalers to $35 RE
India pharma companies develop versions of Wegovy to get in on weight-loss windfall RE
Lupin Gets US FDA Nod for Minzoya Tablets MT
Lupin Limited Receives Approval from U.S. FDA for Minzoyatm CI
Lupin Launches Fertility Medicine Ganirelix in US MT
Lupin Launches Ganirelix Acetate Injection in the United States CI
Lupin Launches Generic Version of Ophthalmic Solution in US MT
Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States CI
Jefferies Upgrades Lupin to Hold From Underperform, Adjusts Price Target to INR430 From INR520 MT
Transcript : Lupin Limited, Q3 2024 Earnings Call, Feb 08, 2024
Lupin's Consolidated Net Profit Jumps in Fiscal Q3 MT
Indian drugmaker Lupin beats quarterly profit estimates on strong demand RE
Lupin Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Lupin Gets US FDA Nod for Bromfenac Ophthalmic Solution MT
Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075% CI
Lupin Limited Receives Approval from U.S. FDA for Dronedarone Tablets, USP CI
Lupin Gets US FDA Tentative Nod for Rivaroxaban Tablets MT
Lupin Gets US FDA Nod for Febuxostat Tablets MT
Lupin Receives Approval from U.S. FDA for Febuxostat Tablets CI
Global markets live: Boeing; SoftwareOne, Apple, Baidu, FedEx... Our Logo
Lupin Gets US FDA Nod for Hypertension Treatment Drug MT
Chart Lupin Limited
More charts
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
1,598 INR
Average target price
1,510 INR
Spread / Average Target
-5.52%
Consensus
  1. Stock
  2. Equities
  3. Stock Lupin Limited - Bombay S.E.
  4. News Lupin Limited
  5. Lupin : Gets US FDA's Approval for Brexpiprazole Tablets